Therapeutic potential of new second generation antipsychotics for major depressive disorder

Bibliography

• Kessler RC, Berglund P, Demler O, The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
   PubMed Web of Science ®Google Scholar
• Ayuso-Mateos JL. Global burden of unipolar depressive disorders in the year 2000, WHO, 2000 Available from: http://www.who.int/healthinfo/statistics/bod_depression.pdf [Last accessed 5 November 2010]
   Google Scholar
• Stewart WF, Ricci JA, Chee E, Cost of lost productive work time among US workers with depression. JAMA 2003;289:3135-44
   PubMed Web of Science ®Google Scholar
• Carney RM, Freedland KE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 2009;166:410-17
   PubMed Web of Science ®Google Scholar
• Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007;52:46-54
   PubMed Web of Science ®Google Scholar
• Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs 2010;2:131-61
   Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Fava M, Trivedi MH, A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;16:1519-1530; quiz 665
   Google Scholar
• Fava M, Rush AJ, Wisniewski SR, A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006;163:1161-72
   PubMed Web of Science ®Google Scholar
• DeBattista C, Hawkins J. Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009;23:369-77
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Muzina DJ, Adams A, Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009;10:3061-75
   PubMed Web of Science ®Google Scholar
• Pae CU, Sohi MS, Seo HJ, Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1165-73
   PubMed Web of Science ®Google Scholar
• Robertson MM, Trimble MR. Major tranquillisers used as antidepressants. A review. J Affect Disord 1982;4:173-93
   PubMed Web of Science ®Google Scholar
• Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201
   PubMed Web of Science ®Google Scholar
• Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66(Suppl 8):30-40
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007;8:1211-19
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Bymaster FP, Meltzer HY, Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008;60:358-403
   PubMed Web of Science ®Google Scholar
• Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000;61(Suppl 6):7-11
   PubMed Web of Science ®Google Scholar
• Shelton RC, Sanders-Bush E, Manier DH, Lewis DA. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 2009;158:1406-15
   PubMed Web of Science ®Google Scholar
• Richardson-Jones JW, Craige CP, Guiard BP, 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 2010;65:40-52
   PubMed Web of Science ®Google Scholar
• Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. J Clin Psychiatry 2004;65(Suppl 4):25-30
   PubMed Web of Science ®Google Scholar
• Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-18
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F, The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-64
   PubMed Web of Science ®Google Scholar
• Pandey DK, Mahesh R, Kumar AA, A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacol Biochem Behav 2010;94:363-73
   PubMed Web of Science ®Google Scholar
• Celada P, Puig M, Amargos-Bosch M, The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252-65
   PubMed Web of Science ®Google Scholar
• Hajos M, Fleishaker JC, Filipiak-Reisner JK, The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004;10:23-44
   PubMedGoogle Scholar
• Candy M, Jones L, Williams R, Psychostimulants for depression. Cochrane Database Syst Rev 2009;(1):CD006722
   Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65
   PubMed Web of Science ®Google Scholar
• Ballas C, Yang C, O'Reardon J, Ziprasidone: a novel psychotropic with unique properties. Expert Rev Neurother 2004;4:179-86
   PubMedGoogle Scholar
• Jensen NH, Rodriguiz RM, Caron MG, N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008;33:2303-12
   PubMed Web of Science ®Google Scholar
• Lee S, Jeong J, Kwak Y, Park SK. Depression research: where are we now? Mol Brain 2010;3:8
   PubMed Web of Science ®Google Scholar
• Molteni R, Calabrese F, Racagni G, Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 2009;124:74-85
   PubMed Web of Science ®Google Scholar
• Bai O, Chlan-Fourney J, Bowen R, Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003;71:127-31
   PubMed Web of Science ®Google Scholar
• Bai O, Zhang H, Li XM. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res 2004;1010:81-6
   PubMed Web of Science ®Google Scholar
• Luo C, Xu H, Li XM. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res 2005;1063:32-9
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Ikenouchi-Sugita A, Hori H, Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:308-12
   PubMed Web of Science ®Google Scholar
• Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22:367-88
   PubMed Web of Science ®Google Scholar
• Weber J, Lyseng-Williamson KA, Scott LJ. Aripiprazole: in major depressive disorder. CNS Drugs 2008;22:807-13
   PubMed Web of Science ®Google Scholar
• Berman RM, Marcus RN, Swanink R, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53
   PubMed Web of Science ®Google Scholar
• Marcus RN, McQuade RD, Carson WH, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Leon AC, Shear MK, Portera L, Klerman GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992;27:78-82
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mankoski R, Baker RA, Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 2010;120:133-40
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Thase ME, Fava M, Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008;69:1928-36
   PubMed Web of Science ®Google Scholar
• Berman RM, Fava M, Thase ME, Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A, Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
   PubMed Web of Science ®Google Scholar
• Nelson JC, Thase ME, Trivedi MH, Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009;11:344-52
   PubMedGoogle Scholar
• Fava M, Wisniewski SR, Thase ME, Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol 2009;29:362-7
   PubMed Web of Science ®Google Scholar
• Debattista C, Debattista K. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr Drug Saf 2010;5:263-6
   PubMedGoogle Scholar
• Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat 2009;5:369-83
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Scott LJ. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010;24:245-62
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4
   PubMed Web of Science ®Google Scholar
• Shelton RC, Williamson DJ, Corya SA, Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289-97
   PubMed Web of Science ®Google Scholar
• Corya SA, Williamson D, Sanger TM, A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-72
   PubMed Web of Science ®Google Scholar
• Thase ME, Corya SA, Osuntokun O, A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-36
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Williamson DJ, Tohen MF, A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004;24:365-73
   PubMed Web of Science ®Google Scholar
• Meyers BS, Flint AJ, Rothschild AJ, A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009;66:838-47
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Thase ME, Osuntokun O, An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009;70:387-96
   PubMed Web of Science ®Google Scholar
• Tohen M, Case M, Trivedi MH, Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010;71:451-62
   PubMed Web of Science ®Google Scholar
• Wijkstra J, Lijmer J, Balk FJ, Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 2006;188:410-5
   PubMed Web of Science ®Google Scholar
• Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am J Psychiatry 2005;162:796-8
   PubMed Web of Science ®Google Scholar
• Corya SA, Andersen SW, Detke HC, Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003;64:1349-56
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88
   PubMed Web of Science ®Google Scholar
• Andersen SW, Clemow DB, Corya SA. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005;66:1468-76
   PubMed Web of Science ®Google Scholar
• McIntyre A, Gendron A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007;24:487-94
   PubMed Web of Science ®Google Scholar
• Garakani A, Martinez JM, Marcus S, A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008;23:269-75
   PubMed Web of Science ®Google Scholar
• Bauer M, Pretorius HW, Constant EL, Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
   PubMed Web of Science ®Google Scholar
• El-Khalili N, Joyce M, Atkinson S, Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:917-32
   PubMed Web of Science ®Google Scholar
• Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 2008;8:73
   PubMed Web of Science ®Google Scholar
• Weisler R, Joyce M, McGill L, Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14:299-313
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Montgomery SA, Feifel D, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-39
   PubMed Web of Science ®Google Scholar
• Bortnick B, El-Khalili N, Banov M, Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2010: published online 9 August 2010 doi:10.1016/j.jad.2010.06.031
   Google Scholar
• Earley W, McIntyre A, Wang G, Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). 8th International Forum on Mood and Anxiety Disorders. Vienna, Austria; 2008. p. P10
   Google Scholar
• Katila H, Mezhebovsky I, Mulroy A, Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD). 8th International Forum on Mood and Anxiety Disorders. Vienna, Austria; 2008. p. P23
   Google Scholar
• Liebowitz M, Lam RW, Lepola U, Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 2010;27:964-76
   PubMed Web of Science ®Google Scholar
• Wijkstra J, Burger H, van den Broek WW, Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010;121:190-200
   PubMed Web of Science ®Google Scholar
• Thase ME. Quetiapine monotherapy for bipolar depression. Neuropsychiatr Dis Treat 2008;4:11-21
   PubMedGoogle Scholar
• Bandelow B, Chouinard G, Bobes J, Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-20
   PubMed Web of Science ®Google Scholar
• Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009;9:1147-58
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Gharabawi GM, Canuso CM, Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006;31:2505-13
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, Pandina GJ, Turkoz I, Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007;147:593-602
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Canuso CM, Gharabawi GM, Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008;16:21-30
   PubMed Web of Science ®Google Scholar
• Reeves H, Batra S, May RS, Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:1228-336
   PubMed Web of Science ®Google Scholar
• Keitner GI, Garlow SJ, Ryan CE, A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009;43:205-14
   PubMed Web of Science ®Google Scholar
• Patton JH, Stanford MS, Barratt ES. Factor structure of the barratt impulsiveness scale. J Clin Psychol 1995;51:768-74
   PubMed Web of Science ®Google Scholar
• Carroll BJ. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation'. Neuropsychopharmacology 2008;33:2546-7; author reply 2548
   PubMed Web of Science ®Google Scholar
• Rosa AR, Franco C, Torrent C, Ziprasidone in the treatment of affective disorders: a review. CNS Neurosci Ther 2008;14:278-86
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA, Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004;65:217-21
   PubMed Web of Science ®Google Scholar
• Dunner DL, Amsterdam JD, Shelton RC, Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007;68:1071-7
   PubMed Web of Science ®Google Scholar
• Bauer M, Whybrow PC, Angst J, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43
   PubMedGoogle Scholar
• Bauer M, Bschor T, Pfennig A, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007;8:67-104
   PubMed Web of Science ®Google Scholar
• Suehs BT, Argo TR, Bendele SD, Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms. The Texas Department of State Health Services; Austin, TX, 2008
   Google Scholar
• Depression: the treatment and management of depression in adults. London, UK: National Institute for Health and Clinical Excellence. 2009. Available from: www.nice.org.uk/CG90 [Last accessed 6 November 2010]
   Google Scholar
• Lam RW, Kennedy SH, Grigoriadis S, Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-43
   PubMed Web of Science ®Google Scholar
• Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010;71(Suppl E1):e04
   Google Scholar
• Kane JM, Jeste DV, Barnes TR, Tardive Dyskinesia a Task Force Report of the American Psychiatric Association. American Psychiatric Association, Washington, DC; 1992
   Google Scholar
• Gao K, Kemp DE, Ganocy SJ, Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28:203-9
   PubMed Web of Science ®Google Scholar
• Kane JM, Fleischhacker WW, Hansen L, Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009;70:627-43
   PubMed Web of Science ®Google Scholar
• Luppino FS, de Wit LM, Bouvy PF, Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010;67:220-9
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Rasgon NL, Kemp DE, Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009;9:51-9
   PubMed Web of Science ®Google Scholar
• Kendler KS, Gardner CO, Fiske A, Gatz M. Major depression and coronary artery disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of comorbidity. Arch Gen Psychiatry 2009;66:857-63
   PubMed Web of Science ®Google Scholar
• Marder SR, Essock SM, Miller AL, Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
   PubMed Web of Science ®Google Scholar
• Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006;28:1912-21
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Lonnqvist J, Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333(7561):224
   PubMed Web of Science ®Google Scholar
• Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf 2007;30:569-79
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43
   PubMed Web of Science ®Google Scholar